Premium
Topical tacrolimus in the management of atopic dermatitis in Japan
Author(s) -
Furue Masutaka,
Uchi Hiroshi,
Moroi Yoichi,
Ogawa Sachiko,
Nakahara Takeshi,
Urabe Kazunori
Publication year - 2006
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2006.00064.x
Subject(s) - medicine , tacrolimus , atopic dermatitis , calcineurin , adverse effect , dermatology , disease , atopy , intensive care medicine , allergy , surgery , pharmacology , immunology , transplantation
Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. Topical steroids are the mainstay of treatment. However, the adverse effects of steroids on hormonal function are the major obstacle for their use as long‐term topical therapy. Topical calcineurin inhibitors, such as tacrolimus, not only complement existing treatment options but also overcome some of the drawbacks of topical steroid therapy and fulfill the long‐term needs of patients in preventing disease progression. Short‐ and long‐term efficacy and safety of topical tacrolimus has been widely recognized and it is also accepted as a first‐line treatment for the inflammation of AD. In order to reduce the possible long‐term adverse effects, it is important to monitor the clinical dose in daily clinics.